ADA 2026 Scientific Sessions: New GLP-1 Drugs and Diabetes Research Highlights
Summary
In this JAMA Medical News podcast, Jennifer Abbasi interviews Dr. Rita Kalyani, the ADA's Chief Scientific and Medical Officer, about key highlights from the American Diabetes Association's 2026 Scientific Sessions in New Orleans. They discuss several major developments in diabetes and obesity research, including a novel oral GLP-1 drug, a combined semaglutide-amylin analogue injection, and data from China on high-dose mazdutide. The conversation covers the latest advancements in treatment options for diabetes and obesity management.
Source
Twitter / XADA 2026 Scientific Sessions: New GLP-1 Drugs and Diabetes Research Highlightsja.maKey quotes
· 3 pulledToday we're bringing you clinical updates from the American Diabetes Association's annual scientific sessions, which recently wrapped up in New Orleans.
Dr. Kalyani is the ADA's Chief Scientific and Medical Officer and a professor of medicine at Johns Hopkins University.
From the JAMA Network, this is the JAMA Medical News podcast, discussing timely topics in clinical medicine, biomedical sciences, public health, and health policy.
You might also wanna read
Semaglutide Shows Chondroprotective Effects in Osteoarthritis Through Weight Loss-Independent Metabolic Mechanism
This research article demonstrates that semaglutide, a GLP-1 receptor agonist, provides chondroprotective effects in osteoarthritis mouse mo
GLP-1 Medications Show Promise for Treating Addiction Through Brain Reward Pathways
The article explores the emerging potential of GLP-1 medications like Ozempic to treat various addictions beyond their original diabetes and
newyorker.com·4mo ago
Police Remove Researchers from ADA Conference Over Editorial on Research Funding Policy Impacts
At the American Diabetes Association (ADA) 2026 conference, police escorted five researchers out of the meeting for distributing an editoria
the-scientist.com·14d ago
AI Analysis of Reddit Posts Identifies Potential Side Effects of GLP-1 Weight Loss Drugs
Researchers at the University of Pennsylvania used AI to analyze over 410,000 Reddit posts spanning six years to identify potential side eff
sciencealert.com·18d ago
GLP-1 Drugs Linked to 30% Lower Breast Cancer Risk in New Study
New research published in the Journal of Clinical Oncology suggests GLP-1 weight loss medications may reduce cancer risk. An observational s
forbes.com·10d ago
Scientists removed from ADA conference for sharing editorial critical of Trump administration's science policies
Five leading scientists, including the editor-in-chief of Diabetes Care and a former ADA president, were ejected from the American Diabetes
arstechnica.com·16d agoComments
Sign in to join the conversation.
No comments yet. Be the first.